HTR1A, TPH2, and 5-HTTLPR Polymorphisms and Their Impact on the Severity of Depressive Symptoms and on the Concentration of Tryptophan Catabolites during Hepatitis C Treatment with Pegylated Interferon-α2a and Oral Ribavirin (PEG-IFN-α2a/RBV)

Cells. 2023 Mar 22;12(6):970. doi: 10.3390/cells12060970.

Abstract

Background: Seeing that there are no data about associations between serotonin gene polymorphism and tryptophan catabolite concentration during PEG-IFN-α2a treatment, the aim of the current study is to examine (a) the associations between polymorphisms within the HTR1A, TPH2, and 5-HTT genes and the severity of depression symptoms and (b) the relationships among rs6295, rs4570625, and 5-HTTLPR rs25531polymorphisms and indoleamine 2,3-dioxygenase (IDO) activity, as well as kynurenine (KYN), tryptophan (TRP), kynurenic acid (KA), and anthranilic acid (AA) concentrations.

Materials and methods: The study followed a prospective, longitudinal, single-center cohort design. The severity of the depressive symptoms of 101 adult patients with chronic HCV infections was measured during PEG-IFN-α2a/RBV treatment. We used the Montgomery-Åsberg Depression Rating Scale (MADRS) to assess the severity of depressive symptoms. The subjects were evaluated six times-at baseline and at weeks 2, 4, 8, 12, and 24. At all the time points, MADRS score, as well as KYN, TRP, KA, and AA concentrations, and IDO activity were measured. At baseline, rs6295, rs4570625, and 5-HTTLPR rs25531polymorphisms were assessed.

Results: Subjects with C/C genotypes of 5-HT1A and lower-expressing alleles (S/S, LG/LG, and S/LG) of 5-HTTLPR scored the highest total MADRS scores and recorded the highest increase in MADRS scores during treatment. We found associations between TRP concentrations and the TPH-2 and 5-HTTLPR rs25531 genotypes.

Conclusions: Our findings provide new data that we believe can help better understand infection-induced depression as a distinct type of depression.

Keywords: 5-HTT; HCV; HTR1A; TPH2; TRYCATs; depression; pegylated interferon-α2a.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use
  • Depression* / genetics
  • Depression* / metabolism
  • Hepatitis C, Chronic* / complications
  • Hepatitis C, Chronic* / drug therapy
  • Hepatitis C, Chronic* / genetics
  • Humans
  • Interferon alpha-2* / adverse effects
  • Interferon alpha-2* / pharmacology
  • Interferon alpha-2* / therapeutic use
  • Kynurenine
  • Polyethylene Glycols / pharmacology
  • Polymorphism, Genetic
  • Prospective Studies
  • Receptor, Serotonin, 5-HT1A / genetics
  • Ribavirin / adverse effects
  • Ribavirin / pharmacology
  • Ribavirin / therapeutic use
  • Tryptophan Hydroxylase / genetics
  • Tryptophan Oxygenase / genetics
  • Tryptophan* / drug effects
  • Tryptophan* / metabolism

Substances

  • Antiviral Agents
  • HTR1A protein, human
  • Interferon alpha-2
  • Kynurenine
  • Polyethylene Glycols
  • Receptor, Serotonin, 5-HT1A
  • Ribavirin
  • SLC6A4 protein, human
  • TPH2 protein, human
  • Tryptophan
  • Tryptophan Hydroxylase
  • Tryptophan Oxygenase

Grants and funding

This study was supported by grants SUBZ.C230.23.076 from Wrocław Medical University, NN402366733 and NN402586140 from the Polish Ministry of Higher Education and National Science Center, Poland (2017/25/B/NZ6/01463).